Home Compare AMGN vs MRK
Stock Comparison · Industry comparison · Drug Manufacturers - General

Amgen vs Merck & Co.: Which Stock Looks Stronger in 2026?

Structurally, Amgen and Merck are closely matched — neither holds a meaningful edge overall. Merck still leads on profitability and valuation, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

On growth, the clearer edge sits with Amgen Inc., while the broader score remains level.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. AMGN and MRK share the same industry classification.

For a similarity-based comparison, see how Amgen and Merck each position within their functional peer groups in AssetNext.

Peer-Relative Score
AMGN
Amgen Inc.
63
Peer-Score
Signal qualityHigh
vs
MRK
Merck & Co., Inc.
63
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in growth.

Dimension spread: AMGN vs MRK Profitability 50 62 Stability 57 57 Valuation 73 88 Growth 75 31 AMGN MRK
Gap Ranking
#1 Growth +44
#2 Valuation +15
#3 Profitability +12
#4 Stability
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AMGN and MRK Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer AMGNMRK Relative valuation Structural strength

Amgen Inc. still looks stronger overall, though current pricing looks more supportive for Merck & Co., Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
On growth, Amgen Inc. ranks near the top of the group; Merck & Co., Inc. sits in the weaker half.
Valuation
On valuation, the edge still sits with Merck & Co., Inc., even though both profiles look solid.
Growth — Dominant Gap
AMGN
75
MRK
31
Gap+44in favour of AMGN

Earnings growth is one contributing factor within the growth lead.

What keeps the gap from being one-sided

Absolute pricing still looks more supportive for Merck, with a forward P/E that is 2.7 turns lower there.

What this means for the comparison

Growth provides the clearer read here, while the broader score remains level.

Explore full peer positioning in AssetNext

Break down the AMGN vs MRK comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-driven comparisons

Explore how AMGN and MRK each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.